Fentora case


The district court has ruled in favor of Watson in a case related Fentora buccal tablet product.

[Law360] [Link]

This ruling is confined to first set of patents

Cephalon sued Watson, Barr and Sandoz for patent infringement of 6200604 & 6974590 for filing ANDA and PIV certification.

Cephalon’s statement “We remain confident in the strength of our claims with respect to the third patent. In the interim, we are reviewing the court’s opinion with respect to the first two patents and are evaluating our options, including an appeal.”

The Third patent is 6,264,981

Updated on 16/03

Cephalon Sues Government to Block Sales of Generic Painkiller Fentora (Bloomberg)

The drugmaker sued the U.S. government today in federal court in Washington seeking to revoke the Food and Drug Administration’s approval of the generic, made by Watson Pharmaceuticals Inc. (WPI), saying the product contains “a novel salt form” never approved by the agency.

Update 25/03/2011

Cephalon Wins FENTORA Patent Suit Against Watson (Press Release) (Bloomberg)

Cephalon announced that today the United States District Court in Delaware upheld the validity of Cephalon’s U.S. Patent Number US 6,264,981 (Expiry Oct 2019) patent and found that Watson Pharmaceuticals, Inc.’s proposed generic version of FENTORA(R) (fentanyl buccal tablet) infringes that patent.

Advertisements

About Guna

Interested to learn things around me
This entry was posted in Patent case and tagged , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s